Testosterone Replacement in Androgen-Deficient Men With Ejaculatory Dysfunction: A Randomized Controlled Trial

Paduch, Darius A.; Polzer, Paula; Ni, Xiao; Basaria, Shehzad

doi:10.1210/jc.2014-4434

Cited by 67 publications

(36 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accordingly, a higher prevalence of hypogonadism was observed in patients with PEVR compared with the rest of the sample without hypogonadism (9.1% vs. 5.3%; P<0.05 after adjustment for age, BMI and smoking habits). Conversely, in a double-blind, randomized, placebo-controlled, 16-week trial with T solution 2% versus placebo (36), T replacement was not associated with significant improvement in ejaculatory dysfunction in androgen-deficient men. Interestingly, the same authors (16) always showed that high T levels increased the odds of DE.…”

Section: Hormonal Regulation Of Ejaculation Functionmentioning

confidence: 94%

Epidemiology of delayed ejaculation

Mollaioli

Gravina

et al. 2016

Transl. Androl. Urol.

View full text Add to dashboard Cite

A large body of literature on diminished ejaculatory disorders has been generated without the use of a clear diagnostic definition. Many studies have not distinguished between the orgasm and ejaculation disorders leading to doubtful results. Delayed ejaculation (DE) is one of the diminished ejaculatory disorders, which range from varying delays in ejaculatory latency to a complete inability to ejaculate. The present review is aimed at providing a comprehensive overview of the current knowledge on the definition and epidemiology of diminished ejaculatory disorders. We focus on the acquired diseases, such as benign prostatic hyperplasia (BPH) and specific drug regimens that may cause an iatrogenic form of ejaculatory disorder. In addition, the impact of aging is discussed since the prevalence of DE appears to be moderately but positively related to age. Finally, we also focus on the importance of the hormonal milieu on male ejaculation. To date, evidence on the endocrine control of ejaculation is derived from small clinical trials, but the evidence suggests that hormones modulate the ejaculatory process by altering its overall latency.

show abstract

Section: Hormonal Regulation Of Ejaculation Functionmentioning

confidence: 94%

Epidemiology of delayed ejaculation

Mollaioli

Gravina

et al. 2016

Transl. Androl. Urol.

View full text Add to dashboard Cite

show abstract

“…Out of 284 retrieved articles, 14 were included in the study [24][25][26][27][28][29][30][31][32][33][34][35][36][37]. However, one study [24] not adequately reporting p values or mean differences was used only when standardized effect size calculations (standardized difference in means [SDM]) were performed.…”

Section: Studies Characteristicsmentioning

confidence: 99%

“…However, one study [24] not adequately reporting p values or mean differences was used only when standardized effect size calculations (standardized difference in means [SDM]) were performed. In addition, in one study [35] only IIEF orgasmic domain was analyzed (Table 1). Available RCTs enrolled 2298 patients, with a mean follow-up of 40.1 wk.…”

Section: Studies Characteristicsmentioning

confidence: 99%

Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores

et al. 2017

View full text Add to dashboard Cite

“…Moreover, voiding symptoms and urinary flow rates were equivalent between the two arms over the duration of the study. Three very recent double-blind, placebo-controlled studies performed on 732 hypogonadal men each failed to identify a clinically and statistically significant relationship between TTh and LUTS compared to placebo [15–17]. …”

Section: Testosterone and Bphmentioning

confidence: 99%

Effects of Testosterone on Benign and Malignant Conditions of the Prostate

Herati

Kohn

Butler

et al. 2017

Curr Sex Health Rep

View full text Add to dashboard Cite

Purpose of the review This review summarizes the current literature regarding the effects of testosterone therapy (TTh) on common disorders of the prostate. Recent Findings Testosterone therapy has gained credibility over the last several decades as a potentially safe co-treatment modality for men with benign and malignant prostatic conditions. Our understanding of the effects of testosterone on the prostate continues to evolve with ongoing clinical and basic science research. Findings of these studies have reinvigorated the debate over the effects of testosterone on benign and malignant disorders of the prostate, including BPH, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and prostate cancer. Summary Despite the burgeoning body of data claiming the safety and efficacy of TTh in common prostatic conditions (including BPH, CP/CPPS, and prostate cancer), diligent monitoring, appropriate patient selection, and informed consent are critical until more definitive studies are performed.

show abstract

Testosterone Replacement in Androgen-Deficient Men With Ejaculatory Dysfunction: A Randomized Controlled Trial

Abstract: T replacement was not associated with significant improvement in EjD in androgen-deficient men.

Cited by 67 publications

References 37 publications

Epidemiology of delayed ejaculation

Epidemiology of delayed ejaculation

Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores

Effects of Testosterone on Benign and Malignant Conditions of the Prostate

Contact Info

Product

Resources

About